Dengue Vaccine

Dengue Vaccine

Global Dengue Vaccine Market to Reach US$1.6 Billion by 2030

The global market for Dengue Vaccine estimated at US$589.0 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 15.8% over the analysis period 2023-2030. Government Institutions End-Use, one of the segments analyzed in the report, is expected to record a 14.2% CAGR and reach US$774.6 Million by the end of the analysis period. Growth in the Hospitals End-Use segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$151.9 Million While China is Forecast to Grow at 20.1% CAGR

The Dengue Vaccine market in the U.S. is estimated at US$151.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$412.8 Million by the year 2030 trailing a CAGR of 20.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 13.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Dengue Vaccine Market - Key Trends and Drivers Summarized

What Is the Dengue Vaccine and How Does It Work Against the Virus?

The dengue vaccine, also known as CYD-TDV or by its commercial name Dengvaxia, is the first vaccine approved for the prevention of dengue disease, caused by the dengue virus. Dengue is transmitted by mosquitoes and is prevalent in tropical and subtropical climates worldwide, affecting millions annually with severe flu-like symptoms and potentially life-threatening complications. The vaccine is a live recombinant tetravalent response to all four virus serotypes, utilizing a weakened version of the yellow fever virus as a vector to express dengue virus proteins. This stimulates the immune system to produce a defense mechanism specifically targeted against the dengue virus if it enters the human body. However, its use is recommended only in populations that are seropositive, meaning they have been previously infected by the virus, as the vaccine can increase the risk of severe dengue in seronegative individuals, those who have never been exposed to the virus.

What Are the Clinical Insights and Public Health Benefits of the Dengue Vaccine?

Clinical trials for the dengue vaccine have shown varied efficacy rates across different serotypes and age groups, with overall efficacy hovering around 60%. The vaccine`s effectiveness is notably higher in individuals who have had a previous dengue infection, underscoring its utility in endemic regions where such exposure is common. Public health benefits of the vaccine include reduced hospitalization rates and a decrease in severe dengue cases, which are significant in helping ease the burden on healthcare systems in affected regions. The vaccine is thus considered a critical tool in the fight against dengue, particularly in high-prevalence areas. By reducing the incidence of dengue, it not only saves lives but also reduces economic loss related to healthcare costs and lost productivity due to illness.

What Are the Challenges and Considerations in the Deployment of the Dengue Vaccine?

The deployment of the dengue vaccine has faced several challenges and ethical considerations. One major issue is determining vaccine eligibility, particularly in identifying individuals previously infected by the dengue virus. This requires reliable serological testing, which can be costly and logistically challenging in resource-poor settings. There`s also the risk of vaccine-related severe dengue in seronegative vaccine recipients, which has led to controversies and public distrust in some regions following early roll-outs. These challenges necessitate careful planning and public communication strategies to maximize benefits and minimize risks associated with vaccination. Additionally, ongoing research and surveillance are crucial to monitor long-term vaccine safety and effectiveness, especially as the virus evolves and different population dynamics come into play.

What Drives the Growth in the Dengue Vaccine Market?

The growth in the dengue vaccine market is driven by several factors, primarily the high burden of disease in over 100 countries, increasing the demand for effective preventive measures. The expansion of endemic areas due to global warming and increased urbanization, which create ideal breeding conditions for mosquitoes, also spur the need for vaccines. Furthermore, growing international travel continues to introduce dengue into new regions, raising global concern and demand for vaccination. Advances in vaccine technology and increased funding for dengue research have accelerated the development and improvement of dengue vaccines, making them more accessible and affordable. Public-private partnerships and initiatives by global health bodies like the World Health Organization (WHO) to promote vaccination as part of integrated dengue prevention plans also contribute to the growth of the market. These factors, combined with a heightened awareness of the impact of dengue and the availability of preventive options, ensure a dynamic and expanding market for the dengue vaccine.

Select Competitors (Total 44 Featured) -

• Biological E. Ltd.
• GlaxoSmithKline plc
• Instituto Butantan
• Panacea Biotec Ltd.
• Sanofi SA
• Takeda Pharmaceuticals Company Ltd.
• Vabiotech

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.